Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-7113b ER vs extended-release oxycodone in opioid-naive patients with cancer pain
jRCT2080222615Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in cancer pain (2 arms), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on jRCT2080222615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222615.